Dyadic International Inc, a global biotechnology company, has announced that it has closed the previously announced sale of substantially all of the assets of its industrial technology business to DuPont’s industrial biosciences business for $75 million in cash. As previously announced, following the closing, Dyadic intends to focus exclusively on its biopharmaceutical business.
Dyadic International uses patented, licensed and proprietary technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins.
